Ravi Viswanathan's Net Worth

$364 Million

Estimate Recalculated Feb 22, 2024 06:34PM EST

Who is Ravi Viswanathan?

Ravi Viswanathan has an estimated net worth of $364 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., Cascadian Therapeutics, Inc., Workday, Inc., Care.com Inc, Millennial Media Inc., AEROHIVE NETWORKS, INC, MULESOFT, INC, Elastic N.V., AVEO PHARMACEUTICALS INC, APPIAN CORP, Mersana Therapeutics, Inc., Clovis Oncology, Inc., Adaptimmune Therapeutics PLC, Duolingo, Inc., BOX INC, Loxo Oncology, Inc., Dermira, Inc., CHAMPIONS ONCOLOGY, INC., Surface Oncology, Inc., GENOCEA BIOSCIENCES, INC., PhaseBio Pharmaceuticals Inc, TESARO, Inc., ARDELYX, INC., GLYCOMIMETICS INC, Tracon Pharmaceuticals, Inc., SYNLOGIC, INC., Epizyme, Inc., Arsanis, Inc., Cerecor Inc., Roka BioScience, Inc., Regulus Therapeutics Inc., ARCA biopharma, Inc., Marker Therapeutics, Inc., Omthera Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc., Strongbridge Biopharma plc, CVENT INC, Achaogen Inc, and INTERLEUKIN GENETICS INC.

SEC CIK

Ravi Viswanathan's CIK is 0001479386

Past Insider Trading and Trends

2018 was Ravi Viswanathan's most active year for acquiring shares with 59 total transactions. Ravi Viswanathan's most active month to acquire stocks was the month of February. 2014 was Ravi Viswanathan's most active year for disposing of shares, totalling 24 transactions. Ravi Viswanathan's most active month to dispose stocks was the month of September. 2016 saw Ravi Viswanathan paying a total of $94,738,980.53 for 55,383,077 shares, this is the most they've acquired in one year. In 2017 Ravi Viswanathan cashed out on 82,295,400 shares for a total of $66,073,750.64, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

PhaseBio Pharmaceuticals Inc (PHASQ) Snapshot price: $0.000001

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
6.64M
$5.00
6.64M
Oct 22
Form 3
0
0
No matching records found

Ra Pharmaceuticals, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+57.31%
2M
$6.00
$12,000,000.00
5.49M
Feb 16
Form 4
3.49M
$11.76
-$5,655.00
3.49M
Oct 31
Form 3
0
0
No matching records found

GLYCOMIMETICS INC (GLYC) Snapshot price: $3.19

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
4.09M
$8.00
4.09M
Jan 15
Form 3
0
0
No matching records found

RHYTHM PHARMACEUTICALS, INC. (RYTM) Snapshot price: $47.96

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+16,613.04%
4.88M
$17.00
4.91M
Oct 10
Form 3
0
0
No matching records found

Cascadian Therapeutics, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-10.88M
0
Mar 9
Form 4
+20.06%
1.82M
$3.30
$5,999,400.00
10.88M
Feb 20
Form 3
0
0
No matching records found